Ontology highlight
ABSTRACT: Background
In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors.Objective
This retrospective multicenter real-world study aims to investigate the potential prognostic value of AEs in patients with HCC treated with atezolizumab plus bevacizumab in the first-line setting.Patients and methods
The study population consisted of 823 patients from five countries (Italy, Germany, Portugal, Japan, and the Republic of Korea).Results
Of the patients, 73.3% presented at least one AE during the study period. The most common AEs were proteinuria (29.6%), arterial hypertension (27.2%), and fatigue (26.0%). In all, 17.3% of the AEs were grade (G) 3. One death due to bleeding was reported. The multivariate analysis confirmed the appearance of decreased appetite G < 2 [versus G ≥ 2; hazard ratio (HR) 0.60; 95% confidence interval (CI) 0.13-0.90; p < 0.01] and immunotoxicity G < 2 (versus G ≥ 2; HR: 0.70; 95% CI 0.24-0.99; p = 0.04) as independent prognostic factors for overall survival, and the appearance of decreased appetite G < 2 (versus G ≥ 2; HR: 0.73; 95% CI 0.43-0.95; p = 0.01), diarrhea (yes versus no; HR: 0.57, 95% CI 0.38-0.85; p = 0.01), fatigue (yes versus no; HR: 0.82, 95% CI 0.65-0.95; p < 0.01), arterial hypertension G < 2 (versus G ≥ 2; HR: 0.68, 95% CI 0.52-0.87; p < 0.01), and proteinuria (yes versus no; HR: 0.79, 95% CI 0.64-0.98; p = 0.03) as independent prognostic factors for progression-free survival.Conclusions
As demonstrated for other therapies, there is also a correlation between the occurrence of AEs and outcomes for patients with HCC for the combination of atezolizumab plus bevacizumab.
SUBMITTER: Persano M
PROVIDER: S-EPMC11230956 | biostudies-literature | 2024 Jul
REPOSITORIES: biostudies-literature
Persano Mara M Rimini Margherita M Tada Toshifumi T Suda Goki G Shimose Shigeo S Kudo Masatoshi M Rossari Federico F Yoo Changhoon C Cheon Jaekyung J Finkelmeier Fabian F Lim Ho Yeong HY Presa José J Masi Gianluca G Bergamo Francesca F Amadeo Elisabeth E Vitiello Francesco F Kumada Takashi T Sakamoto Naoya N Iwamoto Hideki H Aoki Tomoko T Chon Hong Jae HJ Himmelsbach Vera V Iavarone Massimo Alberto MA Cabibbo Giuseppe G Montes Margarida M Foschi Francesco Giuseppe FG Vivaldi Caterina C Soldà Caterina C Sho Takuya T Niizeki Takashi T Nishida Naoshi N Steup Christoph C Bruccoleri Mariangela M Hirooka Masashi M Kariyama Kazuya K Tani Joji J Atsukawa Masanori M Takaguchi Koichi K Itobayashi Ei E Fukunishi Shinya S Tsuji Kunihiko K Ishikawa Toru T Tajiri Kazuto K Ochi Hironori H Yasuda Satoshi S Toyoda Hidenori H Ogawa Chikara C Nishimura Takashi T Hatanaka Takeshi T Kakizaki Satoru S Shimada Noritomo N Kawata Kazuhito K Hiraoka Atsushi A Tada Fujimasa F Ohama Hideko H Nouso Kazuhiro K Morishita Asahiro A Tsutsui Akemi A Nagano Takuya T Itokawa Norio N Okubo Tomomi T Imai Michitaka M Kosaka Hisashi H Naganuma Atsushi A Koizumi Yohei Y Nakamura Shinichiro S Kaibori Masaki M Iijima Hiroko H Hiasa Yoichi Y Foti Silvia S Camera Silvia S Piscaglia Fabio F Scartozzi Mario M Cascinu Stefano S Casadei-Gardini Andrea A
Targeted oncology 20240430 4
<h4>Background</h4>In the context of patients with hepatocellular carcinoma (HCC) treated with systemic therapy, the correlation between the appearance of adverse events (AEs) and reported efficacy outcomes is well-known and widely investigated. From other pathological settings, we are aware of the prognostic and predictive value of the occurrence of immune-related AEs in patients treated with immune-checkpoint inhibitors.<h4>Objective</h4>This retrospective multicenter real-world study aims to ...[more]